332 related articles for article (PubMed ID: 32070029)
1. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.
Ferrín G; Guerrero M; Amado V; Rodríguez-Perálvarez M; De la Mata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070029
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux C; Toso C
Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
[TBL] [Abstract][Full Text] [Related]
4. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.
Veiga SR; Ge X; Mercer CA; Hernández-Álvarez MI; Thomas HE; Hernandez-Losa J; Ramón Y Cajal S; Zorzano A; Thomas G; Kozma SC
Clin Cancer Res; 2018 Aug; 24(15):3767-3780. PubMed ID: 29691292
[No Abstract] [Full Text] [Related]
5. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
6. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
7. Pivotal role of mTOR signaling in hepatocellular carcinoma.
Villanueva A; Chiang DY; Newell P; Peix J; Thung S; Alsinet C; Tovar V; Roayaie S; Minguez B; Sole M; Battiston C; Van Laarhoven S; Fiel MI; Di Feo A; Hoshida Y; Yea S; Toffanin S; Ramos A; Martignetti JA; Mazzaferro V; Bruix J; Waxman S; Schwartz M; Meyerson M; Friedman SL; Llovet JM
Gastroenterology; 2008 Dec; 135(6):1972-83, 1983.e1-11. PubMed ID: 18929564
[TBL] [Abstract][Full Text] [Related]
8. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.
Guerrero M; Ferrín G; Rodríguez-Perálvarez M; González-Rubio S; Sánchez-Frías M; Amado V; Pozo JC; Poyato A; Ciria R; Ayllón MD; Barrera P; Montero JL; de la Mata M
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30650598
[TBL] [Abstract][Full Text] [Related]
9. Celastrus orbiculatus Extracts Inhibit Human Hepatocellular Carcinoma Growth by Targeting mTOR Signaling Pathways.
Qian YY; Li WY; Yan Y; Zhao XY; Yang T; Fang CC; Hou JJ; Liu YQ
Chin J Integr Med; 2019 Nov; 25(11):845-852. PubMed ID: 31127506
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
11. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.
Wang C; Wang X; Su Z; Fei H; Liu X; Pan Q
Oncol Rep; 2015 Oct; 34(4):1708-16. PubMed ID: 26239364
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
13. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
15. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
18. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Ling S; Song L; Fan N; Feng T; Liu L; Yang X; Wang M; Li Y; Tian Y; Zhao F; Liu Y; Huang Q; Hou Z; Xu F; Shi L; Li Y
Int J Oncol; 2017 Jan; 50(1):297-309. PubMed ID: 27959383
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
[TBL] [Abstract][Full Text] [Related]
20. Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.
Wen W; Han T; Chen C; Huang L; Sun W; Wang X; Chen SZ; Xiang DM; Tang L; Cao D; Feng GS; Wu MC; Ding J; Wang HY
Mol Cancer Ther; 2013 Sep; 12(9):1796-804. PubMed ID: 23804702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
